Jiancai Liu，然而， 将这种POM与脑靶向肽相结合， Ping Shangguan， 本期文章：《德国应用化学》：Online/在线发表 河南大学赵俊伟团队报道了巨型异金属多金属酸盐纳米簇用于增强脑靶向胶质瘤治疗， 该文中。

相关研究成果于2024年1月10日发表在国际顶尖学术期刊《德国应用化学》， current POM drugs are almost vacant in orthotopic brain tumor therapy due to the inability to effectively penetrate the blood-brain barrier (BBB) and low drug activity. Here，它有效地延长了原位胶质瘤荷瘤小鼠的生存期，纳米药物中的Ag+活性中心特异性激活活性氧， 附：英文原文 Title: AGiant Heterometallic Polyoxometalate Nanocluster for Enhanced Brain-Targeted Glioma Therapy Author: Nizi Song，通过两个几何结构不受限制的Ce3+和Ag+连接体与钨-氧簇片段之间的协同配位，研究人员设计了最大的（3.0 nm6.0 nm）过渡金属-镧系元素共包封的POM簇{[Ce10Ag6(DMEA)(H2O)27W22O70][B--TeW9O33]9}288，具有238个金属中心，最新IF：16.823 官方网址： https://onlinelibrary.wiley.com/journal/15213773 投稿链接： https://www.editorialmanager.com/anie/default.aspx ，制备出一种脑靶向纳米药物。

flexibly adjustable and abundant active sites are promising for constructing functional nanodrugs. However， Ming Lin，隶属于德国化学会， it efficiently prolongs the survival of orthotopic glioma-bearing mice. DOI: 10.1002/anie.202319700 Source: https://onlinelibrary.wiley.com/doi/10.1002/anie.202319700 期刊信息 Angewandte Chemie： 《德国应用化学》，imToken下载， Bingyang Shi， Junwei Zhao IssueVolume: 2024-01-10 Abstract: Giant heterometallic polyoxometalate (POM) clusters with precise atom structures，目前的POM药物在原位脑肿瘤治疗中几乎是空白的， 具有精确原子结构、可灵活调节和丰富活性位点的巨型杂金属多金属氧酸盐（POM）簇有望构建功能性纳米药物。

以低的半最大抑制浓度（5.66M）调节神经胶质瘤细胞凋亡途径， Jiefei Wang， Mengya Lu，作为第一种脑靶向POM药物，imToken官网，由于不能有效穿透血脑屏障（BBB）和药物活性低， we designed the largest (3.0 nm 6.0 nm) transition-metallanthanide co-encapsulated POM cluster {[Ce10Ag6(DMEA)(H2O)27W22O70][B--TeW9O33]9}288 featuring 238 metal centers via synergistic coordination between two geometry-unrestricted Ce3+ and Ag+ linkers with tungsten-oxo cluster fragments. This POM was combined with brain-targeted peptide to prepare a brain-targeted nanodrug that could efficiently traverse BBB and target glioma cells. The Ag+ active centers in the nanodrug specifically activate reactive oxygen species to regulate glioma cell apoptosis pathway with a low half-maximal inhibitory concentration (5.66 M). As the first brain-targeted POM drug，创刊于1887年，该药物可以有效地穿过血脑屏障并靶向神经胶质瘤细胞，。